MediSapiens

MediSapiens has integrated its Explorer data curation, management, and analytics system with Bluebee's cloud-based NGS data analysis platform.

The Helsinki-based firm plans to offer data solutions on Microsoft's Azure cloud to Finnish healthcare organizations first.

The Finnish bioinformatics firm will aid European researchers and animal-focused diagnostics companies in developing a functional annotation of the dog genome.

The company said it will participate in a feasibility study for the development of personalized medicine decision support systems.

The company will provide informatics support for the consortium, which aims to develop personalized medicine applications that combine genomic and clinical data.

The BeHEARD competition will award more than $600,000 worth of technology products and services for rare disease research projects.

NEW YORK (GenomeWeb) – Finland-based bioinformatics firm MediSapiens said this week that it is ramping up its US operations, including moving its East Cost subsidiary to a bigger office space in Cambridge, Mass., preparing to launch a new website, and planning to hire new staff, most likely in bu

NEW YORK (GenomeWeb) – MediSapiens has announced that it will provide its software solution, dubbed the Integrated Genomics Platform, to Bayer Healthcare.

Startup Silicon Valley Biosystems is hoping to build a diagnostics business by offering genomic data interpretation and sequencing services to clinicians and healthcare providers.

Finnish bioinformatics firm MediSapiens has signed its first customer for OncoGenomics Explorer, a cloud computing-based application launched last September for use in cancer genomics research (

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.